About Us

It Begins with a Vacation

The story of ChinaBio® starts with a vacation... In November 2006, our founder, Greg Scott, visited China for the first time.  He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park.  From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China.  His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more.

So in late January 2007, he returned for one week with only two scheduled meetings.  By the end of the week and over 30 meetings, the seeds of ChinaBio® were sown.  By April, ChinaBio's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired.  While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.

The World Discovers China Biotech

Then, in August 2007, WuXi PharmaTech went public, quickly followed by several other China biotech IPOs.  Suddenly the world knew there was a biotech industry in China and wanted to know more and began beating a path to ChinaBio's door. By early 2008, we had moved to larger offices across the hall and expanded the staff from two to six full time and three part time members.  Mr. Scott had also been interviewed on CCTV-9 and several radio and internet shows.

By the end of 2008, less than two years from our launch, ChinaBio® had organized five major conferences in China, including four ChinaBio® Investor Forums and the BioCapital China Summit in Beijing.  For 2009, we have plans for another six major events in 2009, including our first ChinaBio® Partnering Forum in Shanghai in June, and our first US event in September in San Francisco.

We've also worked with some of the world's most respected pharma and biotech companies, including Roche and Pfizer, and helped China biomedical companies raise over $60M US.  Our in-house research staff tracks China's biotech industry including novel technology development, clinical trial activity, VC investments and M&A and IPO activity.  This information gives us and our clients' critical insights into the direction of the industry and how China will impact the future of the global biopharma industry.

Mr. Scott now makes Shanghai his home, trading the sunshine and beaches of San Diego for the vitality of China.  It surprises even him how quickly things can move in China.